Vertex Pharmaceuticals Incorporated (VRTX) : Jgp Global Gestao De Recursos Ltda. scooped up 1,411 additional shares in Vertex Pharmaceuticals Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 7,231 shares of Vertex Pharmaceuticals Incorporated which is valued at $734,163.Vertex Pharmaceuticals Incorporated makes up approximately 1.10% of Jgp Global Gestao De Recursos Ltda.’s portfolio.
Other Hedge Funds, Including , Delphi Private Advisors reduced its stake in VRTX by selling 2 shares or 40.0% in the most recent quarter. The Hedge Fund company now holds 3 shares of VRTX which is valued at $305.Pinebridge Investments boosted its stake in VRTX in the latest quarter, The investment management firm added 127 additional shares and now holds a total of 309 shares of Vertex Pharmaceuticals Incorporated which is valued at $31,373.Tci Wealth Advisors reduced its stake in VRTX by selling 3 shares or 12.5% in the most recent quarter. The Hedge Fund company now holds 21 shares of VRTX which is valued at $2,125.Foundry Partners reduced its stake in VRTX by selling 33,895 shares or 79.78% in the most recent quarter. The Hedge Fund company now holds 8,590 shares of VRTX which is valued at $754,030. Vertex Pharmaceuticals Incorporated makes up approx 0.07% of Foundry Partners’s portfolio.
Vertex Pharmaceuticals Incorporated closed down -0.15 points or -0.15% at $96.94 with 5,95,225 shares getting traded on Monday. Post opening the session at $97.48, the shares hit an intraday low of $95.57 and an intraday high of $97.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Aug 16, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $108 .
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.